アンチトロンビンIII
同義/類義語：アンチトロンビン, 抗トロンビンIII
英訳・(英)同義/類義語：antithrombin III
血液中に存在するタンパク質で、ヘパリン存在化でトロンビン、活性型第IX因子、X因子と結合してプロテアーゼ活性を阻害市、血栓形成を防止する。
英訳・(英)同義/類義語：antithrombin III
血液中に存在するタンパク質で、ヘパリン存在化でトロンビン、活性型第IX因子、X因子と結合してプロテアーゼ活性を阻害市、血栓形成を防止する。
「生物学用語辞典」の他の用語
| 酵素タンパク質モチーフなど： | アレスチン アロステリック部位 アロステリック酵素 アンチトロンビンIII アンドロゲン アンドロゲン受容体 アンドロゲン結合タンパク質 |
アンチトロンビンIII ( antithrombin III )
アンチトロンビン
(アンチトロンビンIII から転送)
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2021/03/07 07:49 UTC 版)
アンチトロンビン（英: antithrombin、略称: AT）は血液凝固系のいくつかの酵素を不活性化するタンパク質であり、ヒトではSERPINC1遺伝子にコードされる。アンチトロンビンは肝臓で産生される糖タンパク質で、432アミノ酸からなる。3つのジスルフィド結合を含み、4か所のグリコシル化部位が存在する。α-アンチトロンビンは血漿中で優勢な形態のアンチトロンビンで、4つのグリコシル化部位のそれぞれにオリゴ糖が付加されている。より少ない形態であるβ-アンチトロンビンでは、1ヶ所のグリコシル化部位が常に修飾されていない状態である[5]。アンチトロンビンの活性は抗凝固薬であるヘパリンによって何倍にも増大する。ヘパリンはアンチトロンビンの第IIa因子（トロンビン）や第Xa因子への結合を強化する[6]。
| ||||||||||||||||
- ^ a b c GRCh38: Ensembl release 89: ENSG00000117601 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026715 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ a b c Bjork, I; Olson, JE (1997). Antithrombin, A bloody important serpin (in Chemistry and Biology of Serpins). Plenum Press. pp. 17–33. ISBN 978-0-306-45698-5
- ^ Finley, Alan; Greenberg, Charles (2013-06-01). “Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass”. Anesthesia and Analgesia 116 (6): 1210–1222. doi:10.1213/ANE.0b013e31827e4e62. ISSN 1526-7598. PMID 23408671.
- ^ “An antithrombin reaction to prothrombin activation”. Am. J. Physiol. 176 (1): 97–103. (1954). doi:10.1152/ajplegacy.1953.176.1.97. PMID 13124503.
- ^ “Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor”. J. Biol. Chem. 246 (11): 3712–3719. (1971). PMID 4102937.
- ^ “Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration”. Eur. J. Clin. Invest. 7 (1): 27–35. (1977). doi:10.1111/j.1365-2362.1977.tb01566.x. PMID 65284.
- ^ “Molar antithrombin concentration in normal human plasma”. Haemostasis 13 (6): 363–368. (1983). doi:10.1159/000214823. PMID 6667903.
- ^ Jordan RE (1983). “Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism”. Arch. Biochem. Biophys. 227 (2): 587–595. doi:10.1016/0003-9861(83)90488-5. PMID 6607710.
- ^ a b c d “Regulation of thrombin activity by antithrombin and heparin”. Sem. Thromb. Hemost. 20 (4): 373–409. (1994). doi:10.1055/s-2007-1001928. PMID 7899869.
- ^ “Physiological variant of antithrombin-III lacks carbohydrate side-chain at Asn 135”. FEBS Lett 219 (2): 431–436. (1987). doi:10.1016/0014-5793(87)80266-1. PMID 3609301.
- ^ “Expression of functionally active human antithrombin III”. Proceedings of the National Academy of Sciences of the United States of America 84 (11): 3886–3890. (1987). doi:10.1073/pnas.84.11.3886. PMC: 304981. PMID 3473488.
- ^ “Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells”. J. Biol. Chem. 264 (35): 21153–21159. (1989). PMID 2592368.
- ^ “Expression of biologically active human antithrombin III by recombinant baculovirus in Spodoptera frugiperda cells”. J. Biol. Chem. 266 (6): 3995–4001. (1991). PMID 1995647.
- ^ “Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells”. Biochem. J. 310 (Pt 1): 323–330. (1995). doi:10.1042/bj3100323. PMC: 1135891. PMID 7646463.
- ^ a b “Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin”. J. Mol. Biol. 301 (5): 1287–1305. (2000). doi:10.1006/jmbi.2000.3982. PMID 10966821.
- ^ “On the size of the active site in proteases. I. Papain”. Biochem. Biophys. Res. Commun. 27 (2): 157–162. (1967). doi:10.1016/S0006-291X(67)80055-X. PMID 6035483.
- ^ “Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity”. J. Biol. Chem. 276 (31): 29195–29199. (2001). doi:10.1074/jbc.M102187200. PMID 11389142.
- ^ “Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin”. Thromb. Res. 9 (3): 217–222. (1976). doi:10.1016/0049-3848(76)90210-3. PMID 982345.
- ^ “Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor”. FEBS Lett 119 (2): 241–244. (1980). doi:10.1016/0014-5793(80)80262-6. PMID 7428936.
- ^ a b “Probing serpin reactive-loop conformations by proteolytic cleavage”. Biochem. J. 314 (2): 647–653. (1996). doi:10.1042/bj3140647. PMC: 1217096. PMID 8670081.
- ^ a b “Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites”. Biochemistry 42 (27): 8143–8152. (2003). doi:10.1021/bi034363y. PMID 12846563.
- ^ a b “The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin”. J. Biol. Chem. 255 (21): 10081–10090. (1980). PMID 6448846.
- ^ Griffith MJ (1982). “Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin”. J. Biol. Chem. 257 (13): 7360–7365. PMID 7085630.
- ^ “Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects”. J. Biol. Chem. 266 (10): 6353–6354. (1991). PMID 2007588.
- ^ a b “Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement”. J. Biol. Chem. 267 (18): 12528–12538. (1992). PMID 1618758.
- ^ “Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation”. J. Biol. Chem. 281 (46): 35478–35486. (2006). doi:10.1074/jbc.M607204200. PMC: 2679979. PMID 16973611.
- ^ a b c d “Allosteric activation of antithrombin critically depends upon hinge region extension”. J. Biol. Chem. 279 (45): 47288–47297. (2004). doi:10.1074/jbc.M408961200. PMID 15326167.
- ^ a b “The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions”. Nature Structural & Molecular Biology 1 (1): 48–54. (1994). doi:10.1038/nsb0194-48. PMID 7656006.
- ^ a b “Biological implications of a 3 A structure of dimeric antithrombin”. Structure 2 (4): 257–270. (1994). doi:10.1016/S0969-2126(00)00028-9. PMID 8087553.
- ^ “Synthesis of Thrombin inhibiting Heparin mimetics without side effects”. Nature 398 (6726): 417–422. (1999). doi:10.1038/18877. PMID 10201371.
- ^ a b c “Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin”. Nature Structural & Molecular Biology 11 (9): 857–862. (2004). doi:10.1038/nsmb811. PMID 15311269.
- ^ a b “Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity”. J. Mol. Biol. 326 (3): 823–833. (2003). doi:10.1016/S0022-2836(02)01382-7. PMID 12581643.
- ^ “The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change”. Biochemistry 36 (22): 6682–6691. (1997). doi:10.1021/bi9702492. PMID 9184148.
- ^ “Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta”. Arterioscler. Thromb. Vasc. Biol. 16 (10): 1292–1297. (1996). doi:10.1161/01.ATV.16.10.1292. PMID 8857927.
- ^ “Antithrombin and its inherited deficiency states”. Semin. Hematol. 34 (3): 188–204. (1997). PMID 9241705.
- ^ “Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options”. Drugs 67 (10): 1429–1440. (2007). doi:10.2165/00003495-200767100-00005. PMID 17600391.
- ^ “Molecular genetics of antithrombin deficiency”. Blood Rev. 10 (2): 59–74. (1996). doi:10.1016/S0268-960X(96)90034-X. PMID 8813337.
- ^ Egeberg O (1965). “Inherited antithrombin deficiency causing thrombophilia”. Thromb. Diath. Haemorrh. 13: 516–530. doi:10.1055/s-0038-1656297. PMID 14347873.
- ^ “Heterogeneity of the "classical" antithrombin III deficiency”. Thromb. Haemost. 43 (2): 133–136. (1980). doi:10.1055/s-0038-1650034. PMID 7455972.
- ^ “Pleiotropic effects of antithrombin strand 1C substitution mutations”. J. Clin. Invest. 90 (6): 2422–2433. (1992). doi:10.1172/JCI116133. PMC: 443398. PMID 1469094.
- ^ “Antithrombin III: summary of first database update”. Nucleic Acids Res. 22 (17): 3556–3559. (1994). PMC: 308318. PMID 7937056.
- ^ a b Sas G (1984). “Hereditary antithrombin III deficiency: biochemical aspects”. Haematologica 17 (1): 81–86. PMID 6724355.
- ^ a b “Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis”. Thromb. Haemost. 70 (2): 361–369. (1993). doi:10.1055/s-0038-1649581. PMID 8236149.
- ^ “A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection”. Genomics 16 (1): 298–299. (1993). doi:10.1006/geno.1993.1184. PMID 8486379.
- ^ “A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)”. Thromb. Res. 64 (5): 621–625. (1991). doi:10.1016/S0049-3848(05)80011-8. PMID 1808766.
- ^ a b Imperial College London, Faculty of Medicine, Antithrombin Mutation Database. Retrieved on 2008-08-16.
- ^ “Molecular basis of inherited human antithrombin deficiency”. Blood 80 (9): 2159–2171. (1992). PMID 1421387.
- ^ a b “Thrombate III label”. 2013年2月23日閲覧。
- ^ Research, Center for Biologics Evaluation and (2019-04-24). “ATryn” (英語). FDA.
- ^ a b Antithrombin (Recombinant) US Package Insert ATryn for Injection February 3, 2009
- ^ Allingstrup, Mikkel; Wetterslev, Jørn; Ravn, Frederikke B.; Møller, Ann Merete; Afshari, Arash (9 February 2016). “Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis”. Intensive Care Medicine 42 (4): 505–520. doi:10.1007/s00134-016-4225-7. PMC: 2137061. PMID 26862016.
- ^ “Structural basis of latency in plasminogen activator inhibitor-1”. Nature 355 (6357): 270–273. (1992). doi:10.1038/355270a0. PMID 1731226.
- ^ “Commercial antithrombin concentrate contains inactive L-forms of antithrombin”. Thromb. Haemost. 77 (2): 323–328. (1997). doi:10.1055/s-0038-1655962. PMID 9157590.
- ^ “Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1”. Biochemistry 36 (42): 13133–13142. (1997). doi:10.1021/bi970664u. PMID 9335576.
- ^ “The conformational basis of thrombosis”. Thromb. Haemost. 86 (1): 14–22. (2001). doi:10.1055/s-0037-1616196. PMID 11487000.
- ^ a b c “Formation of the antithrombin heterodimer in vivo and the onset of thrombosis”. Blood 94 (10): 3388–3396. (1999). PMID 10552948.
- ^ “A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity”. J. Biol. Chem. 276 (15): 11996–12002. (2001). doi:10.1074/jbc.M010170200. PMID 11278631.
- ^ O'Reilly MS (2007). “Antiangiogenic antithrombin”. Semin. Thromb. Hemost. 33 (7): 660–666. doi:10.1055/s-2007-991533. PMID 18000792.
- ^ “Antiangiogenic activity of the cleaved conformation of the serpin antithrombin”. Science 285 (5435): 1926–1928. (1999). doi:10.1126/science.285.5435.1926. PMID 10489375.
[続きの解説]
「アンチトロンビン」の続きの解説一覧
「アンチトロンビン III」の例文・使い方・用例・文例
- アンチトロンビンIIIのページへのリンク
